Can Avonib (Tosovo) completely cure patients with acute myeloid leukemia?

Ivosidenib is an oral small molecule IDH1 inhibitor, mainly used to treat patients with acute myeloid leukemia (AML) who carry IDH1 gene mutations. Its mechanism of action is to inhibit the activity of mutant IDH1enzyme, thereby blocking the abnormal accumulation of 2-hydroxyglutarate (2-HG) and restoring the normal differentiation of leukemia cells. This mechanism provides a new approach to targeted therapy for AML patients, especially for patients who have poor response to standard chemotherapy regimens or who cannot tolerate intensive chemotherapy.

As to whether it can be completely cured, existing clinical studies show that ivonib can significantly improve the complete remission rate (CR) and duration of remission in patients carrying IDH1 mutationsAML, but "complete cure" is still relatively limited. Some patients can achieve long-term remission with long-term use, but AML itself is highly heterogeneous and has a risk of recurrence. Even in CR status, residual lesions or gene clonal evolution may still occur, leading to disease recurrence. Therefore, ivonib is regarded more as an important means to control the disease and prolong progression-free survival, rather than as an absolute cure.

In combination treatment strategies, ivonib is combined with low-intensity chemotherapy or drugs such as azacitidine to further improve response rates and survival. Some studies have shown that combination therapy can enhance leukemia cell differentiation and apoptosis and reduce the risk of relapse. But even so, treatment still requires individualized management, and regular monitoring of bone marrow and hematological indicators to evaluate efficacy and adjust medication. For some patients who are suitable for stem cell transplantation, ivonib can be used as a bridging treatment to enable patients to meet transplant conditions and improve their chances of long-term survival.

Overall, Ivosidenib (Ivosidenib) has significant targeted efficacy in IDH1mutatedAML patients and can improve survival and quality of life, but it is not yet universally possible to achieve a complete cure. Clinically, individualized treatment plans should be formulated based on the patient's specific condition, gene mutation status and tolerance, combined with regular follow-up and combined strategies to maximize the efficacy and prolong progression-free survival, and provide a more reliable long-term management plan for AML patients.

Keyword tags: ivonib,IDH1inhibitor, acute myeloid leukemia, targeted therapy, post-transplantation adjuvant

Reference materials:https://go.drugbank.com/drugs/DB14568